These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
389 related articles for article (PubMed ID: 30576866)
1. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Kishnani PS; Rockman-Greenberg C; Rauch F; Bhatti MT; Moseley S; Denker AE; Watsky E; Whyte MP Bone; 2019 Apr; 121():149-162. PubMed ID: 30576866 [TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of asfotase alfa in adults with pediatric-onset hypophosphatasia. Seefried L; Kishnani PS; Moseley S; Denker AE; Watsky E; Whyte MP; Dahir KM Bone; 2021 Jan; 142():115664. PubMed ID: 32987199 [TBL] [Abstract][Full Text] [Related]
3. Investigation of ALPL variant states and clinical outcomes: An analysis of adults and adolescents with hypophosphatasia treated with asfotase alfa. Kishnani PS; Del Angel G; Zhou S; Rush ET Mol Genet Metab; 2021 May; 133(1):113-121. PubMed ID: 33814268 [TBL] [Abstract][Full Text] [Related]
4. Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial. Whyte MP; Simmons JH; Moseley S; Fujita KP; Bishop N; Salman NJ; Taylor J; Phillips D; McGinn M; McAlister WH Lancet Diabetes Endocrinol; 2019 Feb; 7(2):93-105. PubMed ID: 30558909 [TBL] [Abstract][Full Text] [Related]
5. Asfotase alfa therapy for children with hypophosphatasia. Whyte MP; Madson KL; Phillips D; Reeves AL; McAlister WH; Yakimoski A; Mack KE; Hamilton K; Kagan K; Fujita KP; Thompson DD; Moseley S; Odrljin T; Rockman-Greenberg C JCI Insight; 2016 Jun; 1(9):e85971. PubMed ID: 27699270 [No Abstract] [Full Text] [Related]
6. Safety, pharmacokinetics, and pharmacodynamics of efzimfotase alfa, a second-generation enzyme replacement therapy: phase 1, dose-escalation study in adults with hypophosphatasia. Dahir KM; Shannon A; Dunn D; Voegtli W; Dong Q; Hasan J; Pradhan R; Pelto R; Pan WJ J Bone Miner Res; 2024 Sep; 39(10):1412-1423. PubMed ID: 39135540 [TBL] [Abstract][Full Text] [Related]
7. No vascular calcification on cardiac computed tomography spanning asfotase alfa treatment for an elderly woman with hypophosphatasia. Whyte MP; McAlister WH; Mumm S; Bierhals AJ Bone; 2019 May; 122():231-236. PubMed ID: 30825650 [TBL] [Abstract][Full Text] [Related]
8. Asfotase Alfa: A Review in Paediatric-Onset Hypophosphatasia. Scott LJ Drugs; 2016 Feb; 76(2):255-62. PubMed ID: 26744272 [TBL] [Abstract][Full Text] [Related]
9. Recovery of bone mineralization and quality during asfotase alfa treatment in an adult patient with infantile-onset hypophosphatasia. Rolvien T; Schmidt T; Schmidt FN; von Kroge S; Busse B; Amling M; Barvencik F Bone; 2019 Oct; 127():67-74. PubMed ID: 31152801 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of asfotase alfa in patients with hypophosphatasia: A systematic review. Shirinezhad A; Esmaeili S; Azarboo A; Tavakoli Y; Hoveidaei AH; Zareshahi N; Ghaseminejad-Raeini A Bone; 2024 Nov; 188():117219. PubMed ID: 39089608 [TBL] [Abstract][Full Text] [Related]
11. Hypophosphatasia: From Diagnosis to Treatment. Simon S; Resch H; Klaushofer K; Roschger P; Zwerina J; Kocijan R Curr Rheumatol Rep; 2018 Sep; 20(11):69. PubMed ID: 30203264 [TBL] [Abstract][Full Text] [Related]
13. Dual X-ray absorptiometry has limited utility in detecting bone pathology in children with hypophosphatasia: A pooled post hoc analysis of asfotase alfa clinical trial data. Simmons JH; Rush ET; Petryk A; Zhou S; Martos-Moreno GÁ Bone; 2020 Aug; 137():115413. PubMed ID: 32417537 [TBL] [Abstract][Full Text] [Related]
14. Asfotase alfa: enzyme replacement for the treatment of bone disease in hypophosphatasia. Hofmann C; Seefried L; Jakob F Drugs Today (Barc); 2016 May; 52(5):271-85. PubMed ID: 27376160 [TBL] [Abstract][Full Text] [Related]
15. Hypophosphatasia: presentation and response to asfotase alfa. Alsarraf F; Ali DS; Almonaei K; Al-Alwani H; Khan AA; Brandi ML Osteoporos Int; 2024 Apr; 35(4):717-725. PubMed ID: 37993691 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of treatment with asfotase alfa in patients with hypophosphatasia: Results from a Japanese clinical trial. Kitaoka T; Tajima T; Nagasaki K; Kikuchi T; Yamamoto K; Michigami T; Okada S; Fujiwara I; Kokaji M; Mochizuki H; Ogata T; Tatebayashi K; Watanabe A; Yatsuga S; Kubota T; Ozono K Clin Endocrinol (Oxf); 2017 Jul; 87(1):10-19. PubMed ID: 28374482 [TBL] [Abstract][Full Text] [Related]
17. Hypophosphatasia: Enzyme Replacement Therapy Brings New Opportunities and New Challenges. Whyte MP J Bone Miner Res; 2017 Apr; 32(4):667-675. PubMed ID: 28084648 [TBL] [Abstract][Full Text] [Related]
19. Asfotase alfa treatment for 1 year in a 16 year-old male with severe childhood hypophosphatasia. Bowden SA; Adler BH Osteoporos Int; 2018 Feb; 29(2):511-515. PubMed ID: 29046930 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia. Pan WJ; Pradhan R; Pelto R; Seefried L J Clin Pharmacol; 2021 Oct; 61(10):1334-1343. PubMed ID: 33822385 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]